{"id":"NCT00634114","sponsor":"AstraZeneca","briefTitle":"Reflux Esophagitis Phase III Study (Maintenance Treatment)","officialTitle":"A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":null,"completion":"2009-05","firstPosted":"2008-03-12","resultsPosted":"2010-06-17","lastUpdate":"2010-06-17"},"enrollment":540,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Reflux Esophagitis"],"interventions":[{"type":"DRUG","name":"Esomeprazole","otherNames":["Nexium"]},{"type":"DRUG","name":"Esomeprazole","otherNames":["Nexium"]},{"type":"DRUG","name":"Omeprazole","otherNames":["Prilosec"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once daily for 24 weeks on maintenance of Reflux Esophagitis in patients with healed reflux esophagitis in comparison with omeprazole 10 mg once daily and esomeprazole 10 mg once daily by assessment of presence/absence of recurrence of Reflux Esophagitis throughout the treatment period (from the randomisation to the treatment completion) according to the Los Angeles classification.","primaryOutcome":{"measure":"Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"Experimental: Esomeprazole 20 mg","deltaMin":174,"sd":null},{"arm":"Experimental: Esomeprazole 10 mg","deltaMin":166,"sd":null},{"arm":"Comparator: Omeprazole 10 mg","deltaMin":156,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":44,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":188},"commonTop":["Nasopharyngitis","Abdominal pain upper","Diarrhoea","Blood creatine phosphokinase increased","Gastrooesophageal reflux disease"]}}